BRPI0514408B8 - preparação liquida de peptídeo fisiologicamente ativo - Google Patents
preparação liquida de peptídeo fisiologicamente ativoInfo
- Publication number
- BRPI0514408B8 BRPI0514408B8 BRPI0514408A BRPI0514408A BRPI0514408B8 BR PI0514408 B8 BRPI0514408 B8 BR PI0514408B8 BR PI0514408 A BRPI0514408 A BR PI0514408A BR PI0514408 A BRPI0514408 A BR PI0514408A BR PI0514408 B8 BRPI0514408 B8 BR PI0514408B8
- Authority
- BR
- Brazil
- Prior art keywords
- acid
- physiologically active
- liquid preparation
- ghrelins
- active peptide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF] (Somatoliberin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-244339 | 2004-08-24 | ||
JP2004244339 | 2004-08-24 | ||
PCT/JP2005/015362 WO2006022301A1 (ja) | 2004-08-24 | 2005-08-24 | 生理活性ペプチド液状製剤 |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0514408A BRPI0514408A (pt) | 2008-06-10 |
BRPI0514408B1 BRPI0514408B1 (pt) | 2021-02-23 |
BRPI0514408B8 true BRPI0514408B8 (pt) | 2021-05-25 |
Family
ID=35967510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0514408A BRPI0514408B8 (pt) | 2004-08-24 | 2005-08-24 | preparação liquida de peptídeo fisiologicamente ativo |
Country Status (11)
Country | Link |
---|---|
US (2) | US20080193997A1 (pt) |
EP (1) | EP1800689B1 (pt) |
JP (1) | JP4951344B2 (pt) |
KR (1) | KR101149454B1 (pt) |
CN (1) | CN101022822B (pt) |
AU (1) | AU2005275779B2 (pt) |
BR (1) | BRPI0514408B8 (pt) |
CA (1) | CA2576473C (pt) |
ES (1) | ES2620326T3 (pt) |
IL (1) | IL181348A (pt) |
WO (1) | WO2006022301A1 (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2021030A2 (en) * | 2006-04-21 | 2009-02-11 | Amgen, Inc. | Buffering agents for biopharmaceutical formulations |
KR101466933B1 (ko) * | 2006-07-11 | 2014-12-01 | 큐피에스 엘엘씨 | 펩타이드의 지속 방출 전달을 위한 의약 조성물 |
WO2011104557A1 (en) * | 2010-02-24 | 2011-09-01 | Arecor Limited | Protein formulations |
US9103841B2 (en) * | 2011-08-25 | 2015-08-11 | Lsi Medience Corporation | Method for determining glucagon-like peptide-1, and kit for use in said method |
IN2014MN01470A (pt) * | 2012-01-20 | 2015-04-17 | Lupin Ltd | |
CN103301058A (zh) * | 2013-06-17 | 2013-09-18 | 深圳翰宇药业股份有限公司 | 一种特立帕肽注射用组合物及其制备方法和制剂 |
EP2823808A1 (en) * | 2013-07-09 | 2015-01-14 | Ipsen Pharma S.A.S. | Pharmaceutical composition for a sustained release of lanreotide |
NL2015865B1 (en) | 2015-11-27 | 2017-06-13 | Le Vet B V | Maropitant Formulation. |
EP3685849A4 (en) * | 2017-09-22 | 2021-12-22 | Asahi Kasei Pharma Corporation | LIQUID PHARMACEUTICAL COMPOSITION CONTAINING TRIPARATIDE WITH EXCELLENT STABILITY |
US20200289622A1 (en) | 2017-09-22 | 2020-09-17 | Asahi Kasei Pharma Corporation | Teriparatide-containing liquid pharmaceutical composition having excellent pharmacokinetics and/or safety |
CN116718762A (zh) * | 2023-06-09 | 2023-09-08 | 上海品峰医疗科技有限公司 | 一种多肽类样本稳定剂 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB770075A (en) * | 1954-03-15 | 1957-03-13 | Cutter Lab | Improvements in or relating to preparation of a fibrinogen product and stable solutions thereof |
JPH0651637B2 (ja) | 1985-03-28 | 1994-07-06 | エーザイ株式会社 | ペプタイドの吸着防止組成物 |
JPH0669956B2 (ja) | 1988-09-30 | 1994-09-07 | 旭化成工業株式会社 | ポリペプタイド類の吸着防止剤 |
JPH032136A (ja) | 1989-05-30 | 1991-01-08 | Asahi Glass Co Ltd | 複金属シアン化物錯体の製造方法,およびその用途 |
JPH0397083A (ja) | 1989-09-08 | 1991-04-23 | Tokyo Electric Co Ltd | ラベル発行装置 |
DE4126983A1 (de) | 1991-08-15 | 1993-02-18 | Boehringer Mannheim Gmbh | Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke |
SE9201073D0 (sv) * | 1992-04-03 | 1992-04-03 | Kabi Pharmacia Ab | Protein formulation |
SE9300105D0 (sv) * | 1993-01-15 | 1993-01-15 | Kabi Pharmacia Ab | Stable protein solution |
US5482931A (en) | 1993-06-29 | 1996-01-09 | Ferring Ab | Stabilized pharmaceutical peptide compositions |
DE4340781C3 (de) * | 1993-11-30 | 2000-01-27 | Novartis Ag | Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung |
TW426523B (en) * | 1995-04-06 | 2001-03-21 | Hoffmann La Roche | Interferon solution |
US5780431A (en) * | 1996-09-20 | 1998-07-14 | Neurobiological Technologies, Inc. | Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form |
DE69729880T3 (de) * | 1996-12-24 | 2012-05-10 | Biogen Idec Ma Inc. | Stabile flüssige interferon-zubereitungen |
CN1317967A (zh) * | 1998-09-17 | 2001-10-17 | 伊莱利利公司 | 蛋白质制剂 |
US20020061838A1 (en) * | 2000-05-17 | 2002-05-23 | Barton Holmquist | Peptide pharmaceutical formulations |
EP1301200A2 (en) * | 2000-05-19 | 2003-04-16 | Bionebraska, Inc. | Peptide pharmaceutical formulations |
EP1353683A4 (en) | 2000-05-30 | 2004-05-12 | Merck & Co Inc | ANALOGS BY GHRELIN |
DE60224284T2 (de) * | 2001-06-28 | 2008-12-18 | Novo Nordisk A/S | Stabile formulierung von modifiziertem glp-1 |
JP5000848B2 (ja) | 2002-05-21 | 2012-08-15 | 第一三共株式会社 | グレリン含有医薬組成物 |
EP1407779A1 (en) * | 2002-10-10 | 2004-04-14 | Gastrotech A/S | Use of ghrelin for treating low body weight and body fat in gastrectomized individuals |
-
2005
- 2005-08-24 CA CA2576473A patent/CA2576473C/en active Active
- 2005-08-24 KR KR1020077006467A patent/KR101149454B1/ko active IP Right Grant
- 2005-08-24 CN CN2005800285946A patent/CN101022822B/zh active Active
- 2005-08-24 ES ES05774895.6T patent/ES2620326T3/es active Active
- 2005-08-24 BR BRPI0514408A patent/BRPI0514408B8/pt not_active IP Right Cessation
- 2005-08-24 WO PCT/JP2005/015362 patent/WO2006022301A1/ja not_active Application Discontinuation
- 2005-08-24 EP EP05774895.6A patent/EP1800689B1/en active Active
- 2005-08-24 AU AU2005275779A patent/AU2005275779B2/en active Active
- 2005-08-24 JP JP2006531949A patent/JP4951344B2/ja active Active
- 2005-08-24 US US11/660,406 patent/US20080193997A1/en not_active Abandoned
-
2007
- 2007-02-15 IL IL181348A patent/IL181348A/en active IP Right Grant
-
2010
- 2010-08-02 US US12/848,638 patent/US8969298B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP1800689A1 (en) | 2007-06-27 |
EP1800689B1 (en) | 2016-12-28 |
KR20070057850A (ko) | 2007-06-07 |
CA2576473A1 (en) | 2006-03-02 |
BRPI0514408B1 (pt) | 2021-02-23 |
JP4951344B2 (ja) | 2012-06-13 |
EP1800689A4 (en) | 2009-09-23 |
US20110077195A1 (en) | 2011-03-31 |
IL181348A (en) | 2014-06-30 |
CN101022822B (zh) | 2012-06-27 |
US20080193997A1 (en) | 2008-08-14 |
AU2005275779A1 (en) | 2006-03-02 |
US8969298B2 (en) | 2015-03-03 |
KR101149454B1 (ko) | 2012-05-25 |
CA2576473C (en) | 2015-06-30 |
IL181348A0 (en) | 2007-07-04 |
AU2005275779B2 (en) | 2011-09-15 |
CN101022822A (zh) | 2007-08-22 |
JPWO2006022301A1 (ja) | 2008-05-08 |
BRPI0514408A (pt) | 2008-06-10 |
ES2620326T3 (es) | 2017-06-28 |
WO2006022301A1 (ja) | 2006-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0514408B8 (pt) | preparação liquida de peptídeo fisiologicamente ativo | |
Ngo et al. | Angiotensin-I converting enzyme inhibitory peptides from antihypertensive skate (Okamejei kenojei) skin gelatin hydrolysate in spontaneously hypertensive rats | |
Hintzen et al. | In vivo evaluation of an oral self-microemulsifying drug delivery system (SMEDDS) for leuprorelin | |
Do et al. | Cationic membrane‐active peptides–anticancer and antifungal activity as well as penetration into human skin | |
Stach et al. | Combining Topology and Sequence Design for the Discovery of Potent Antimicrobial Peptide Dendrimers against Multidrug‐Resistant Pseudomonas aeruginosa | |
Tulipano et al. | Whey proteins as source of dipeptidyl dipeptidase IV (dipeptidyl peptidase-4) inhibitors | |
ATE523209T1 (de) | Flüssige formulierung von fsh | |
US9820938B2 (en) | Stable liquid formulation of AMG 416 (etelcalcetide) | |
JP2020196762A (ja) | 熱傷及び二次性合併症の予防及び治療方法 | |
KR20080042843A (ko) | 치료제의 점막 전달 향상을 위한 밀착 연접 조절 펩티드성분 | |
CN102791279A (zh) | 用于进行冠状动脉旁路移植手术的方法 | |
BRPI0508933A (pt) | composições para entrega tópica | |
WO2007135196A3 (en) | Stable soluble salts of phenylbenzimidazole sulfonic acid at phs at or below 7.0 | |
RU2657535C2 (ru) | Гели для местного применения, содержащие с-концевые пептиды альфа-коннексина (act) | |
WO2010030670A3 (en) | Compositions and methods for the prevention of oxidative degradation of proteins | |
Maggio et al. | Oral delivery of octreotide acetate in Intravail® improves uptake, half-life, and bioavailability over subcutaneous administration in male Swiss webster mice | |
Nishimoto et al. | An endostatin-derived peptide orally exerts anti-fibrotic activity in a murine pulmonary fibrosis model | |
CA2846598A1 (en) | Treatment of degenerative joint disease | |
CN105658201A (zh) | 促性腺激素的制剂 | |
US9763994B2 (en) | Composition for promoting wound healing | |
BR112022004674A2 (pt) | Ácido canforsulfônico e combinações do mesmo com excipientes catiônicos como agentes de redução de viscosidade em formulações de proteína altamente concentradas | |
He et al. | Effects of salvianolic acid A on plasma and tissue dimethylarginine levels in a rat model of myocardial infarction | |
Dening et al. | Enhancing intestinal absorption of a model macromolecule via the paracellular pathway using E-Cadherin peptides | |
Kros | Drug delivery via cell membrane fusion using lipopeptide modified liposomes | |
Thibado et al. | Cholesterol Influence on Arginine-Containing Transmembrane Peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved |
Owner name: KENJI KANGAWA (JP) , ASUBIO PHARMA CO., LTD. (JP) Free format text: ALTERADO DE: DAIICHI ASUBIO PHARMA CO., LTD. |
|
B25A | Requested transfer of rights approved |
Owner name: KENJI KANGAWA (JP) , DAIICHI SANKYO COMPANY LIMITE Free format text: TRANSFERIDO POR FUSAO DE: ASUBIO PHARMA CO., LTD. |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/02/2021, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/08/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 16A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2634 DE 29-06-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
B15V | Prolongation of time limit allowed |
Free format text: REFERENTE A PETICAO NO 870210117577 DE 17/12/2021 - RECONHECIDA A JUSTA CAUSA, DE ACORDO COM O ARTIGO 221 DA LPI 9279/96, SERA CONCEDIDO AO REQUERENTE O PRAZO ADICIONAL DE 15 (QUINZE) DIAS CONTADOS A PARTIR DA DATA DESTA PUBLICACAO PARA A REGULARIZACAO DO PAGAMENTO DAS ANUIDADES |
|
B21H | Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2634 DE 29/06/2021 POR TER SIDO INDEVIDA. |
|
B24E | Patent annual fee: resolution cancelled |
Free format text: ANULADA A PUBLICACAO CODIGO 24.10 NA RPI NO 2650 DE 19/10/2021 POR TER SIDO INDEVIDA, UMA VEZ QUE A DEVOLUCAO DE PRAZO FOI CONCEDIDO. |